A Multicenter, Open-Label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503, CA1P) as Monotherapy in Subjects with Primary or Secondary Hepatic Tumour Burden.

Trial Profile

A Multicenter, Open-Label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503, CA1P) as Monotherapy in Subjects with Primary or Secondary Hepatic Tumour Burden.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Combretastatin A1 phosphate (Primary)
  • Indications Cancer metastases; Liver cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mateon Therapeutics
  • Most Recent Events

    • 11 Jan 2011 Planned end date changed from 1 Jul 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 07 Jun 2010 Trial design details were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010). Current enrolment is in cohort 2 of the phase Ib portion.
    • 20 May 2010 Trial design data will be presented in a poster at the 2010 ASCO Annual Meeting, according to an OXiGENE media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top